ConductScience.org, home

Comparison · NCT04322682-169a024b

Colchicine vs Placebo: Number of Participants Who Required Mechanical Ventilation in the 30 Days Following Randomization.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Colchicine vs Placebo: Number of Participants Who Required Mechanical Ventilation in the 30 Days Following Randomization. Trial comparisons, record NCT04322682-169a024b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04322682-169a024b

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.004920.002750.00879wilson
Risk in group 20.009320.00610.0142wilson
Risk difference, group 1 minus group 2-0.0044-0.009750.000633newcombe hybrid score
Risk ratio, group 1 over group 20.5280.2551.09log
Odds ratio, group 1 over group 20.5260.2531.09log
Number needed to treat, for one fewer participant with the outcome on Colchicine than on Placebo227from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Colchicine
Patients in this arm will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
112,235OG000
Group 2PlaceboPatients will receive the placebo 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.212,253OG001

Outcome

Type
SECONDARY
Title
Number of Participants Who Required Mechanical Ventilation in the 30 Days Following Randomization.
Description
The secondary endpoint is the need for mechanical ventilation in the 30 days following randomization.
Time frame
30 days post randomization
Population

Source ClinicalTrials.gov

Trial

Title
Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)
NCT number
NCT04322682
Phases
PHASE3
Conditions
Corona Virus Infection
Interventions
Colchicine, Placebo oral tablet
Lead sponsor
Montreal Heart Institute
Results first posted
2021-09-08

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04322682-169a024b